HOME >> MEDICINE >> NEWS
Studies compare hysterectomy vs. other medical treatments for abnormal uterine bleeding

udy for authors' financial disclosures.

EDITORIAL: EVALUATING GYNECOLOGICAL SURGICAL PROCEDURES

In an accompanying editorial, Roy M. Pitkin, M.D., from the University of California, Los Angeles, and James R. Scott, M.D., from the University of Utah, Salt Lake City, discuss these two randomized controlled studies. "The clinical trials by Kuppermann et al and Hurskainen et al represent important efforts to place a common surgical procedure on firmer, evidence-based grounds."

"One fairly consistent finding in the two investigations is the proportion of women in the control group who, for whatever reason, had hysterectomies (42 percent in the Finnish trial and 52 percent in the U.S. trial). If this result applies to the general population - and in view of the recruitment [of participants for the studies] problems it may not - then women with unsatisfactory response to such first-line 'medical' therapy for excessive uterine bleeding can be counseled that further conservative therapy carries approximately a 50 percent likelihood of ultimately leading to a hysterectomy. ... Does it mean that surgery will likely be necessary eventually anyway, so perhaps better sooner than later, sparing the woman continued symptoms? Or does it mean that there is a 50 percent chance of avoiding the hysterectomy and these odds are worth taking to avoid a major operation?"

The editorial authors suggest that additional randomized clinical trials with longer follow-up are needed "to determine whether these (or other) more conservative treatments are more efficacious and cost-effective in the long run than hysterectomy."

(JAMA. 2004; 291:1503-1504. Available post-embargo at JAMA.com)


'"/>

Contact: Eve Harris
415-885-7277
JAMA and Archives Journals
23-Mar-2004


Page: 1 2 3 4

Related medicine news :

1. Studies underscore genetic involvement in nicotine addiction & aggressive hostility
2. Studies address issues of risk and survival in rapidly increasing GI cancers
3. Studies examine coffee drinking and risk of liver and colorectal cancers
4. Studies reveal physicians attitudes on end-of-life care
5. Studies from the November issue of The Archives of Dermatology, a theme issue on facial rejuvenation
6. Studies link obesity to increased frequency of heartburn symptoms; greater risk of esophageal cancer
7. Studies demonstrate positive data in treatment of hepatitis C
8. Studies examine risk factors and potential consequences associated with prehypertension
9. Studies show ACTOS(R) (pioglitazone HCl) has positive effects on various components of dyslipidemia
10. Studies identify risk factors for colon cancer
11. Studies indicate healthy eating may affect cancer development, improve digestive system

Post Your Comments:
(Date:7/30/2014)... 2014. A new network of 25 regional stroke centers ... (NIH StrokeNet) is working to change the way ... advances of the last two decades, stroke remains a ... or disability for 795,000 Americans. The numbers are expected ... , To accelerate the pace of progress, NIH ...
(Date:7/30/2014)... OR (PRWEB) July 30, 2014 LTC Consumer, ... evaluate long term care insurance, features an Instant Quote tool ... Director and co-founder of LTC Consumer. Quotes are free and ... a click in only seven areas – including age, gender, ... on screen within seconds (you don’t need to enter any ...
(Date:7/30/2014)... The Institute for Integrative Nutrition (IIN), ... Arianna Huffington has joined as a guest speaker and is ... Training Program . , Arianna Huffington is the chair, president, ... blogging site that won a Pulitzer Prize in 2012 for ... was included on the Forbes “Most Powerful Women” list of ...
(Date:7/30/2014)... July 30, 2014 (HealthDay News) -- For patients with ... enough to trigger airway inflammation for at least 24 ... what you smell, but also what you think you ... Chemical Senses Center in Philadelphia, said in a Monell ... scents and fragrances. When we expect that an odor ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 According ... and Machine Vision Market by Technology (ICS, MES, ... Embedded), Components (Camera, FGOL), Application (Process, Discrete) - ... published by MarketsandMarkets, the Mexican market is expected ... 6.18% by 2020. , Browse 70 market data ...
Breaking Medicine News(10 mins):Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:LTC Consumer Launches Online Tool for Getting Instant Long Term Care Insurance Estimates 2Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 2Health News:Arianna Huffington Joins Integrative Nutrition as a Guest Speaker 3Health News:Even Thinking an Odor is Harmful May Spur Asthma Symptoms 2Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Mexico Factory Automation and Machine Vision Market Worth $6.99 Billion by 2020 - New Report by MarketsandMarkets 4
(Date:7/30/2014)... 30, 2014   Epic Sciences, Inc. ... and develops novel diagnostics to personalize and advance ... the completion of a $30 million Series C ... RusnanoMedInvest (RMI) and Arcus Ventures, existing investors Domain ... as well as undisclosed individual investors. With the ...
(Date:7/30/2014)... 2014 Die Apex Medical Corporation ... Bereich Atemtherapie- und Druckzonenprodukte, gibt bekannt, dass ... Deutschland anfechten werden. Dieses hat entschieden, dass ... von ResMed verletze. Apex weist darauf hin, ... verschiedene Patente von ResMed Anfechtungen wegen Nichtigkeit ...
(Date:7/29/2014)... Amgen (NASDAQ: AMGN ) today announced financial ... include: , Total revenues increased 11 percent to ... by strong performance across the portfolio, particularly Enbrel ® ... (denosumab) and XGEVA ® (denosumab). , Adjusted ... revenues and a significant increase in the profitability of ...
Breaking Medicine Technology:Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25
Cached News: